Mechanisms of action of anti-immunoglobulin E therapy

Allergy and Asthma Proceedings

Volumn 27, Issue 2 SUPPL. 1, 2006, Pages

  Soresi, Simona ^a   Togias, Alkis ^a,b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS ASTHMA AND ALLERGY CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTI-IGE; ANTIIDIOTYPIC ANTIBODY; IMMUNOGLOBULIN E; IMMUNOGLOBULIN E ANTIBODY; MONOCLONAL ANTIBODY; OMALIZUMAB;

ASTHMA; BASOPHIL; COMPARATIVE STUDY; CONFERENCE PAPER; DESENSITIZATION; DRUG EFFECT; FEMALE; HUMAN; HYPERSENSITIVITY; IMMUNOLOGY; MALE; MAST CELL; PHYSIOLOGY; RISK FACTOR; TREATMENT OUTCOME;

ANTIBODIES, ANTI-IDIOTYPIC; ANTIBODIES, MONOCLONAL; ASTHMA; BASOPHILS; DESENSITIZATION, IMMUNOLOGIC; FEMALE; HUMANS; HYPERSENSITIVITY; IMMUNOGLOBULIN E; MALE; MAST CELLS; RISK FACTORS; TREATMENT OUTCOME;

EID: 33646484417     PISSN: 10885412     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (94)

1. Ishizaka K, and Ishizaka T. Identification of IgE antibodies as a carrier of reaginic activity. J Immunol 99:1187-1198, 1967.
2. Johansson SG. Raised levels of a new immunoglobulin class (IgND) in asthma. Lancet 2:951-953, 1967.
3. MacGlashan D, Schleimer R, Peters S, et al. Comparative studies of human basophils and mast cells. Fed Proc 42:2504-2509, 1983.
4. MacGlashan D Jr, and Lichtenstein LM. Studies of antigen binding on human basophils. I. Antigen binding and functional consequences. J Immunol 130:2330-2336, 1983.
5. MacGlashan DW Jr. Releasability of human basophils: Cellular sensitivity and maximal histamine release are independent variables. J Allergy Clin Immunol 91:605-615, 1993.
6. Henry AJ, Cook JP, McDonnell JM, et al. Participation of the N-terminal region of Cε3 in the binding of human IgE to its high-affinity receptor FεRI. Biochemistry 36:15568-15578, 1997.
7. Presta L, Shields R, O'Connell L, et al. The binding site on human immunoglobulin E for its high affinity receptor. J Biol Chem 269:26368-26373, 1994.
8. Wright JD, and Lim C. Prediction of an anti-IgE binding site on IgE. Protein Eng 11:421-427, 1998.
9. Lin H, Boesel K, Griffith D, et al. Omalizumab rapidly decreases nasal allergic response and FcεRI on basophils. J Allergy Clin Immunol 113:297-302, 2004.
10. Soler M, Matz J, Townley R, et al. The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics. Eur Resp J 18:254-261, 2001.
11. MacGlashan D, Bochner B, Adelman D, et al. Down-regulation of FcεRI expression on human basophils during in vivo treatment of atopic patients with anti-IgE antibody therapy. J Immunol 158:1438-1445, 1997.
12. Prussin C, Griffith D, Boesel K, et al. Omalizumab treatment downregulates dendritic cell FcεRI expression. J Allergy Clin Immunol 112:1147-1154, 2003.
13. Gould HJ, Sutton BJ, Beavil AJ, et al. The biology of IgE and the basis of allergic disease. Annu Rev Immunol 21:579-628, 2003.
14. Wan T, Beavil R, Fabliane S, et al. The crystal structure of IgE Fc reveals an asymmetrically bent conformation. Nat Immunol 3:681-686, 2002.
15. Novak N, and Bieber T. To bend or not to bend. Nat Immunol 3:607-608, 2002.
16. Lichtenstein LM, Sobotka AK, Malveaux FJ, and Gillespie E. IgE-induced changes in human basophil cyclic AMP levels. Int Arch Allergy Appl Immunol 56:473-478, 1978.
17. Kitamura Y, Shimada M, Go S, et al. Distribution of mast-cell precursors in hematopoeitic and lymphopoietic tissues of mice. J Exp Med 150:482-490, 1979.
18. Djukanovic R, Wilson S, Kraft M, et al. Effects of treatment with anti-immunologlobulin E antibody omalizumab on airway inflammation in allergic asthma. Am J Respir Crit Care Med 170:583-593, 2004.
19. MacGlashan D Jr, and Lichtenstein LM. Basic characteristics of human lung mast cell desensitization. J Immunol 139:501-505, 1987.
20. Bousquet J, Wenzel S, Holgate S, et al. Predicting response to omalizumab, an anti-IgE antibody, in patients with allergic asthma. Chest 125:1378-1386, 2004.
21. Beck L, Marcotte G, MacGlashan D, et al. Omalizumab-induced reductions in mast cell FcεRI expression and function. J Allergy Clin Immunol 114:527-530, 2004.
22. Malveaux F, Conroy M, Adkinson N, and Lichtenstein L. IgE receptor on human basophils: Relationship to serum IgE concentration. J Clin Invest 62:176-181, 1978.
23. MacGlashan D Jr, McKenzie-White J, Chichester K, et al. In vitro regulation of FcεRIα expression on human basophils by IgE antibody. Blood 91:1633-4163, 1998.
24. Saini S, MacGlashan D, Sterbinsky S, et al. Down-regulation of human basophil IgE and FcεRIα surface densities and mediator release by anti-IgE-infusions is reversible in vitro and in vivo. J Immunol 162:5624-5630, 1999.
25. MacGlashan D Jr, Xia HZ, Schwartz LB, and Gong J. IgE-regulated loss, not IgE-regulated synthesis, controls expression of FcεRI in human basophils. J Leukoc Biol 70:207-218, 2001.
26. Saini S, and MacGlashan D. How IgE upregulates the allergic response. Curr Opin Immunol 14:694-697, 2002.
27. Borkowski TA, Jouvin MH, Lin SY, and Kinet JP. Minimal requirements for IgE-mediated regulation of surface FcεRI. J Immunol 167:1290-1296, 2001.
28. Marone G, Triggiani M, and de Paulis A. Mast cells and basophils: Friends as well as foes in bronchial asthma? Trends Immunol 26:25-31, 2005.
29. Schroeder J, Lichtenstein L, Roche E, et al. IL-4 production by human basophils found in the lung following segmental allergen challenge. J Allergy Clin Immunol 107:265-271, 2001.
30. Bradding P. The role of the mast cell in asthma: a reassessment. Curr Opin Allergy Clin Immunol 3:45-50, 2003.
31. Crivellato E, Beltrami CA, Mallardi F, and Ribatti D. The mast cell: An active participant or an innocent bystander? Histol Histopathol 19:259-270, 2004.
32. Brown J, Tyler C, Jones C, et al. Tryptase, the dominant secretory granular protein in human mast cells, is a potent mitogen for cultured dog tracheal smooth muscle cells. Am J Respir Cell Mol Biol 13:227-236, 1995.
33. Cairns J, and Walls A. Mast cell tryptase is a mitogen for epithelial cells. J Immunol 156:275-283, 1996.
34. Sommerhoff C. Mast cell tryptases and airway remodeling. Am J Respir Crit Care Med 164:S52-S58, 2001.
35. Berger P, Perng D-W, Thabrew H, et al. Tryptase and agonists of PAR-2 induce the proliferation of human airway smooth muscle cells. J Appl Physiol 91:1372-1379, 2001.
36. Gordins P, Purkiss J, Lackie P, et al. The inhibition of epithelial repair by mast cell chymase. J Allergy Clin Immunol 115:S206, 2005.
37. Phipps S, Benyahia F, Ou T-T, et al. Acute allergen-induced airway remodeling in atopic asthma. Am J Respir Cell Mol Biol 31:626-632, 2004.
38. Boulet L, Chapman K, Cote J, et al. Inhibitory effects of an anti-IgE antibody E25 on allergen-induced early asthmatic responses. Am J Respir Crit Care Med 155:1835-1840, 1997.
39. Fahy J, Cockcroft D, Boulet L-P, et al. Effect of aerosolized anti-IgE (E25) on airway responses to inhaled allergen in asthmatic subjects. Am J Respir Crit Care Med 160:1023-1027, 1999.
40. Togias A, Corren J, Shapiro G, et al. Anti-IgE treatment reduces skin test (ST) reactivity. J Allergy Clin Immunol 101:S171, 1998.
41. Lin H, Boesel K, Griffith D, et al. Omalizumab rapidly decreases nasal allergic responses and FcεRI on basophils. J Allergy Clin Immunol 113:297-302, 2004.
42. Corren J, Diaz-Sanchez D, Saxon A, et al. Effects of omalizumab, a humanized monoclonal anti-IgE antibody, on nasal reactivity to allergen and local IgE synthesis. Ann Allergy Asthma Immunol 93:243-248, 2004.
43. Hanf G, Noga O, O'Connor A, and Kunkel G. Omalizumab inhibits allergen challenge-induced nasal response. Eur Resp J 23:414-418, 2004.
44. Ong Y, Menzies-Gow A, Barkans J, et al. Anti-IgE (omalizumab) inhibits late-phase reactions and inflammatory cells after repeat skin allergen challenge. J Allergy Clin Immunol 116:558-564, 2005.
45. Leynadier F, Doudou O, Gaouar H, et al. Effect of omalizumab in health care workers with occupational latex allergy. J Allergy Clin Immunol 2004:360-361, 2004.
46. Leung D, Sampson H, Yunginger J, et al. Effect of anti-IgE therapy (TNX-901) in patients with severe peanut allergy. J Allergy Clin Immunol 111:S274, 2003.
47. Enerback L. Mucosal mast cells in the rat and in man. Int Archs Allergy Appl Immunol 82:249-255, 1987.
48. Fokkens W, Godthelp T, Holm A, et al. Dynamics of mast cells in the nasal mucosa of patients with allergic rhinitis and non-allergic controls: A biopsy study. Clin Exp Allergy 22:701-710, 1992.
49. Kleinjan A, Buhring H-J, McEuen A, et al. Alterations in mast cell phenotype and basophil numbers in the nasal mucosa following repeated low dose allergen challenge in allergic rhinitis. J Allergy Clin Immun 107:S284, 2001.
50. Naclerio R, Proud D, Togias A, et al. Inflammatory mediators in late antigen-induced rhinitis. N Engl J Med 313:65-70, 1985.
51. Bascom R, Wachs M, Naclerio R, et al. Basophil influx occurs after nasal antigen challenge: Effects of topical corticosteroid pretreatment. J Allergy Clin Immunol 81:580-589, 1988.
52. Naclerio R, Kagey-Sobotka A, Lichtenstein L, et al. Observations on nasal late phase reactions. Immunol Invest 16:649-685, 1988.
53. Iliopoulos O, Baroody F, Naclerio R, et al. Histamine-containing cells obtained from the nose hours after antigen challenge have functional and phenotypic characteristics of basophils. J Immunol 148:2223-2228, 1992.
54. Guo C, Liu M, Galli S, et al. Identification of IgE-bearing cells in the late-phase response to antigen in the lung as basophils. Am J Respir Cell Mol Biol 10:384-390, 1994.
55. Plewako H, Arvidsson M, Petruson K, et al. The effect of omalizumab on nasal allergic inflammation. J Allergy Clin Immunol 110:68-71, 2002.
56. von Buboff D, Geiger E, and Bieber T. Antigen-presenting cells in allergy. J Allergy Clin Immunol 108:329-339, 2001.
57. Lambrecht B. Dendritic cells and the regulation of the allergic immune response. Allergy 60:271-282, 2005.
58. Matsuda H, Suda T, Hashizume H, et al. Alteration of balance between myeloid dendritic cells and plasmacytoid dendritic cells in peripheral blood of patients with asthma. Am J Respir Crit Care Med 166:1050-1054, 2002.
59. Constant S, Brogdon J, Piggott D, et al. Resident lung antigen-presenting cells have the capacity to promote Th2 T cell differentiation in situ. J Clin Invest 110:1441-1448, 2002.
60. Moller G, Overbeek S, Van Helden-Meeuwsen CG, et al. Increased numbers of dendritic cells in the bronchial mucosa of atopic asthmatic patients: Downregulation by inhaled corticosteroids. Clin Exp Allergy 26:517-524, 2004.
61. Liu YJ. IPC: Professional type 1 interferon-producing cells and plasmacytoid dendritic cell precursors. Annu Rev Immunol 23:275-306, 2005.
62. Lambrecht B, De Veerman M, Coyle A, et al. Myeloid dendritic cells induce Th2 responses to inhaled antigen, leading to eosinophilic airway inflammation. J Clin Invest 106:551-559, 2000.
63. Krug A, Rothenfusser S, Hornung V, et al. Identification of CpG oligonucleotide sequences with high induction of IFN-alpha/beta in plasmacytoid dendritic cells. Eur J Immunol 31:2154-2163, 2001.
64. Foster B, Metcalfe D, and Prussin C. Human dendritic cell 1 and dendritic cell 2 subsets express FcεRI: Correlation with serum IgE and allergic asthma. J Allergy Clin Immunol 112:1132-1138, 2003.
65. Novak N, Allam J-P, Hagemann T, et al. Characterization of FcεRI-bearing CD123+ blood dendritic cell antigen-2+ plasmacytoid dendritic cells in atopic dermatitis. J Allergy Clin Immunol 114:364-370, 2004.
66. Beeren I, Bruin-Weller M, Ra C, et al. Expression of FcεRI on dendritic cell subsets in peripheral blood of patients with atopic dermatitis and allergic asthma. J Allergy Clin Immunol 116:228-229, 2005.
67. Novak N, Kraft S, and Bieber T. Unraveling the mission of FcεRI on antigen-presenting cells. J Allergy Clin Immunol 111:38-44, 2003.
68. Schroeder JT, Bieneman AP, Xiao H, et al. TLR9- and FcεRI-mediated responses oppose one another in plasmacytoid dendritic cells by down-regulating receptor expression. J Immunol 175:5724-5731, 2005.
69. Chang T, Davis F, Sun N, et al. Monoclonal antibodies specific for human IgE-producing B cells: A potential therapeutic for IgE-mediated allergic diseases. Biotechnology 8:122-127, 1990.
70. Haba S, and Nisonoff A. Effects of syngeneic anti-IgE antibodies on the development of IgE memory and on the secondary IgE response. J Immunol 152:51-57, 1994.
71. Yanagihara Y, Kajiwara K, Ikizawa K, et al. Recombinant soluble form of the human high-affinity immunoglobulin E (IgE) receptor inhibits IgE production through its specific binding to IgE-bearing B cells. J Clin Invest 94:2162-2165, 1994.
72. Haak-Frendscho M, Robbins K, Lyon R, et al. Administration of an anti-IgE antibody inhibits CD23 expression and IgE production in vivo. Immunology 82:306-313, 1994.
73. Chang T. The pharmacological basis of anti-IgE therapy. Nat Biotechnol 18:157-162, 2000.
74. Busse W, Corren J, Lanier B, et al. Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma. J Allergy Clin Immunol 108:184-196, 2001.
75. Ayres J, Higgins B, Chilvers E, et al. Efficacy and tolerability of anti-immunoglobulin E therapy with omalizumab in patients with poorly controlled (moderate-to-severe) allergic asthma. Allergy 59:701-708, 2004.
76. Humbert M, Beasley R, Ayres J, et al. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE. Allergy 60:309-316, 2005.
77. Johnston S, Pattemore P, Sanderson G, et al. Community study of role of viral infections in exacerbations of asthma in 9-11 year old children. BMJ 310:1225-1229, 1995.
78. Green RM, Custovic A, Sanderson G, et al. Synergism between allergens and viruses and risk of hospital admission with asthma: Case-control study. BMJ 324:763, 2002.
79. Murray C, Simpson A, and Custovic A. Allergens, viruses, and asthma exacerbations. Proc Am Thorac Soc 1:99-104, 2004.
80. Xepapadaki X, Papadopoulos N, Bossios A, et al. Duration of postviral airway hyperresponsiveness in children with asthma: Effect of atopy. J Allergy Clin Immunol 116:299-304, 2005.
81. Buhl R, Hanf G, Soler M, et al. The anti-IgE antibody omalizumab improves asthma-related quality of life in patients with allergic asthma. Eur Respir J 20:1088-1094, 2002.
82. Finn A, Gross G, van Bavel J, et al. Omalizumab improves asthma-related quality of life in patients with severe allergic asthma. J Allergy Clin Immunol 111:278-284, 2003.
83. Adelroth E, Rak S, Haahtela T, et al. Recombinant humanized mAb-E25, an anti-IgE mAb, in birch pollen-induced seasonal allergic rhinitis. J Allergy Clin Immunol 106:253-259, 2000.
84. Casale T, Condemi J, LaForce C, et al. Effect of omalizumab on symptoms of seasonal allergic rhinitis. A randomized controlled trial. JAMA 286:2956-2967, 2001.
85. Kuehr J, Brauburger J, Zielen S, et al. and A. t. O. R. S. Group. Efficacy of combination treatment with anti-IgE plus specific immunotherapy in polysensitized children and adolescents with seasonal allergic rhinitis. J Allergy Clin Immunol 109:274-280, 2002.
86. Chervinsky P, Casale T, Townley R, et al. Omalizumab, an anti-IgE antibody, in the treatment of adults and adolescents with perennial allergic rhinitis. Ann Allergy Asthma Immunol 91:160-167, 2003.
87. Greening A, Ind P, Northfield M, and Shaw G. Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid. Lancet 344:219-224, 1994.
88. Pauwels R, Lofdahl C-G, Postma D, et al. Effect of inhaled formoterol and budesonide on exacerbations of asthma. N Engl J Med 337:1405-1411, 1997.
89. Taylor KJ, and Luksza AR. Peripheral blood eosinophil counts and bronchial responsiveness. Thorax 42:452-456, 1987.
90. Woodruff P, Khashayer R, Lazarus S. Relationship between airway inflammation, hyperresponsiveness, and obstruction in asthma. J Allergy Clin Immunol 108:753-758, 2001.
91. Hughes J, Rimmer S, Salome C, et al. Eosinophilia, interleukin-5, and tumour necrosis factor-alpha in asthmatic children. Allergy 56:412-418, 2001.
92. Louis R, Sele J, Henket M, et al. Sputum eosinophil count in a large population of patients with mild to moderate steroid-naive asthma: Distribution and relationship with methacholine bronchial hyperresponsiveness. Allergy 57:907-912, 2002.
93. Leckie M, Brinke A, Khan J, et al. Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyperresponsiveness, and the late asthmatic response. Lancet 356:2144-2148, 2000.
94. Fahy J, Fleming H, Wong H, et al. The effect of an anti-IgE monoclonal antibody on the early- and late-phase responses to allergen inhalation in asthmatic subjects. Am J Respir Crit Care Med 155:1828-1834, 1997.